| Delta 4–SEVERAL: investment, 202104 financing round Series A €multi-million closing with addit funding from European Family Office |
2021-04-07 |
| Stimit–Dräger: investment, 202104 acquisition of majority share in Stimit AG by Drägerwerk AG & Co KGaA |
2021-04-01 |
| Pyxis Oncology–SEVERAL: investment, 202103 financing round Series B $152m led by Arix Bioscience |
2021-03-30 |
| Amphista Therapeutics–SEVERAL: investment, 202103 financing round Series B £38m ($53m) co-led by Forbion + Gilde Healthcare |
2021-03-17 |
| GenMark–Roche: investment, 202103– acquisition $1.8b recommended cash tender offer at $24.05/share premium of 43% |
2021-03-15 |
| Monte Rosa Therapeutics–SEVERAL: investment, 202103 financing round Series C $95m led by new investor Avoro Capital Advisors |
2021-03-12 |
| Relief Therapeutics–OTHER: investment, 202103 private placement CHF10m with 41.5m shares at CHF0.2412/share with institutional US investor |
2021-03-12 |
| AgomAb Therapeutics–SEVERAL: investment, 202103 financing round Series B $74m led by new investor Redmile Group |
2021-03-10 |
| BioPhero–SEVERAL: investment, 202103 financing round Series A $17m led by DCVC Bio with FMC Ventures + Syngenta Ventures + Novo Holdings |
2021-03-09 |
| Lophius–Mikrogen: investment, 202103 acquisition of assets + technologies incl takeover of entire team + lab in Regensburg by Mikrogen |
2021-03-08 |
| Bruker–Cowen: investor conference, 202103 supply service Bruker presents at Cowen & Co Annual Health Care Conference 2021 |
2021-03-02 |
| Kairos GmbH–Iqvia: investment, 202103 acquisition of Kairos GmbH by Iqvia |
2021-03-01 |
| Silicon Therapeutics–Roivant: investment, 202102– acquisition $450m in shares + milestones by Roivant Sciences ANNOUNCED |
2021-02-26 |
| Bruker–SVB: investor conference, 202102 supply service Bruker presents at SVB Leerink Global Healthcare Conference |
2021-02-25 |
| Tetramer Shop–10x Genomics: investment, 202102 acquisition €na of Tetramer Shop ApS by 10x Genomics Inc |
2021-02-24 |
| Vividion Therapeutics–SEVERAL: investment, 202102 financing round Series C $135m co-led by new investors Logos Capital + Boxer Capital |
2021-02-24 |
| Ginolis–Cellink: investment, 202102–202103 acquisition 100% of Ginolis debt/cash-free for €65.7m with €41.6m in cash + €24.1m in shares |
2021-02-15 |
| Abingworth–SEVERAL: investment, 202102 final closing at $465m of Abingworth Bioventures 8 Fund |
2021-02-03 |
| Genopis–Wacker: investment, 202102 acquisition of Genopis Inc for $39m in cash + milestones from Helixmith Co Ltd + Medivate Partners LLC |
2021-02-03 |
| Avacta–Bruker: MS-based SARS-CoV-2 test, 202101– collab developm of BAMS SARS-CoV-2 assay on Bruker MALDI-TOF as IVD test |
2021-01-28 |
| Enthera–Roche: investment, 202101 financing round Series A extension to final closing at €35m with new investor Roche Venture Fund |
2021-01-28 |
| GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences |
2021-01-26 |
| Microcaps–SEVERAL: investment, 202101 seed financing round CHF5m co-led by Helvetica Capital + ZKB |
2021-01-26 |
| Cellvie–SEVERAL: investment, 202101 seed financing round $5m led by Kizoo Technology Capital |
2021-01-25 |
| CureVac–SEVERAL: investment, 202101– follow-on public offering $450m+$67.5m with 5m+750k common shares at $90/share |
2021-01-25 |
| i3 Membrane–SEVERAL: investment, 202101 financing round 7-figure € sum from HTGF + three private investors |
2021-01-25 |
| TScan Therapeutics–SEVERAL: investment, 202101 financing round Series C $100m incl new investors Black Rock + RA Capital |
2021-01-25 |
| Numares–Bruker: NMR spectroscopy, 202102– collab developm + product integration Axinon platform for metabolomics-based NMR-CDx |
2021-01-21 |
| Biophytis–SEVERAL: investment, 202101– US IPO of ADSs up to $14.5m at Nasdaq |
2021-01-20 |
| LignoPure–SEVERAL: investment, 202101 seed financing round €2.2m from HTGF + IFH + Tanovis AG |
2021-01-18 |
| IO Biotech–SEVERAL: investment, 202101 financing round Series B €127m led by new investor HBM Healthcare Investments |
2021-01-13 |
| Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share |
2021-01-12 |
| Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based |
2021-01-11 |
| Boehringer–Alphabet: quantum computing, 202101–202312 collab research + implementation of quantum computing in pharma RnD with Google Quantum AI |
2021-01-11 |
| Kymab–Sanofi: investment, 202101 acquisition $1.1b upfront + $350m milestones ANNOUNCED |
2021-01-11 |
| Labforward–SEVERAL: investment, 202101 financing round Series B >€5m led by Tecan + incl 2mag + Peppermint VenturePartners |
2021-01-11 |
| Novartis–BeiGene: tisleizumab, 202101– license $650m upfront + royalties + milestones developm + commercialisation in US, CA, MX + Europe + RU + JP |
2021-01-11 |
| AmpTec–Merck (DE): investment, 202101 acquisition €na of AmpTec GmbH bei Merck |
2021-01-07 |
| BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al |
2021-01-07 |
| Adeptrix–SEVERAL: investment, 202101 financing round Series A closed with new + minority investor Bruker Corp |
2021-01-06 |
| Somatex Medical Technologies–Hologic: investment, 202101 acquisition $64m of Somatex by Hologic |
2021-01-04 |
| Biosun Biochemicals–BRAIN: investment, 202101 acquisition 100% €na by BRAIN AG |
2021-01-01 |
| Qiagen–Wellcome Trust: COSMIC Database, 202101– distribution excl rights to license + distribute COSMIC for commercial use |
2021-01-01 |
| SomaLogic–SEVERAL: investment, 202012 financing round Series A 2nd closing additional $81m bringing total Series A to $204m or $214m |
2020-12-22 |
| Evotec–Alloy Therapeutics: transgenic mouse technolgy, 202012– supply access to ATX-Gx platform to expand Evotec antibody discovery platform |
2020-12-21 |
| Peptilogics–SEVERAL: investment, 202012 financing round Series B $35.4m led by Presight Capital |
2020-12-21 |
| Cadent Therapeutics–Novartis: investment, 202012– acquisition $210m upfront + $560m milestones ANNOUNCED |
2020-12-17 |
| MYR GmbH–Gilead Sciences: investment, 202012 acquisition €1.15b in cash + €300m milestones of MYR GmbH by Gilead Sciences Inc |
2020-12-10 |
| NBE Therapeutics–Boehringer: investment, 202012– acquisition up to €1.18b by Boehringer |
2020-12-10 |
| Resolve Biosciences–SEVERAL: investment, 202012 financing round Series A $24m co-led by PS Capital Management + MasterMind Advisory Services |
2020-12-10 |
| Curexsys–SEVERAL: investment, 202012 seed financing round €8.2m led by Evotec + Sartorius |
2020-12-09 |
| Boehringer–Proxygen: molecular glue degraders, 202012– collab + license agreem developm in combi with PROTACs against oncogenic targets |
2020-12-07 |
| MaaT Pharma–SEVERAL: investment, 202012 financing round Series B extension €7.35m led by Bpifrance bringing total Series B to €25.35m |
2020-12-01 |
| Noema Pharma–SEVERAL: investment, 202012 financing round Series A CHF54m ($59m) co-led by Sofinnova Partners + Polaris Partners |
2020-12-01 |
| Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED |
2020-12-01 |
| Adrenomed–SEVERAL: investment, 202011 financing round Series E €22.2m co-led by Wellington Partners + HBM |
2020-11-30 |
| BioNTech–InstaDeep: AI-based drug discovery, 202011– strategic collab incl joined AI Innovation Lab to develop immunotherapies |
2020-11-25 |
| Emergence Therapeutics–SEVERAL: investment, 202011 follow-on seed financing round led by HTGF |
2020-11-25 |
| Innatera Nanosystems–SEVERAL: investment, 202011 seed financing round €5m co-lead by MIG Verwaltungs AG + btov Industrial Technologies Fund |
2020-11-25 |
| Atai Life Sciences–SEVERAL: investment, 202011 financing round Series C $125m incl $32m converted debt co-led by Apeiron + Peter Thiel + Catalio |
2020-11-23 |
| SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv |
2020-11-19 |
| Pharvaris–SEVERAL: investment, 202011 financing round Series C $80m co-led by Viking Global Investors + General Atlantic |
2020-11-18 |
| Roche–Lead Pharma: small-molecule immuno modulators, 202011– collab + license agreem up to €260m incl €10m upfront plus royalties |
2020-11-16 |
| Start Codon–SEVERAL: investment, 202011 closing of Start Codon Fund I LP at £15m incl LPs Novartis International AG + Cambridge Innovation Capital |
2020-11-16 |
| m2p-labs–Danaher: investment, 202011 acquisition of m2p-biolabs by Beckman Coulter Life Sciences |
2020-11-12 |
| Metagenomi–SEVERAL: investment, 202011 financing round Series A $65m co-led by Leaps by Bayer + Humboldt Fund |
2020-11-12 |
| Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV |
2020-11-12 |
| MorphoSys–Cherry Biolabs: Hemibody technology, 202011– license €na to apply Hemibody technology to six exclusive targets |
2020-11-11 |
| Catalym–SEVERAL: investment, 202011 financing round Series B €50m led by Vesalius Biocapital III |
2020-11-10 |
| Vera Therapeutics–Merck (DE): atacicept, 202011– license for 10% equity in Vera + €605m milestones + royalties |
2020-11-09 |
| Memo Therapeutics–SEVERAL: investment, 202011 financing round Series B CHF14m led by Swisscanto by ZKB |
2020-11-05 |
| Corlieve Therapeutics–SEVERAL: investment, 202011 seed financing round from Kurma Partners + Idinvest Partners + Pureos Bioventures |
2020-11-02 |
| Kiadis–Sanofi: investment, 202011– cash tender offer €308m for Kiadis Pharma NV at €5.45 per share (272% premium over closing price on 30 Oct) |
2020-11-02 |
| Polaris Science (SG)–Nynomic: plant phenotyping, 202011– distribution in Singapore + Malaysia of LemnaTec solutions for phenotyping + seed testing |
2020-11-01 |
| TVM–SEVERAL: investment, 202010 final closing of $478m of fund TVM Life Science Innovation II incl Eli Lilly |
2020-10-27 |
| AskBio–Bayer: investment, 202010 acquisition by Bayer for $2b upfront plus $2b milestones |
2020-10-26 |
| Eternygen–SEVERAL: investment, 202010 financing round Series A2 1st closing €5m led by Evotec |
2020-10-26 |
| MD Biosciences–MLM Medical Labs: investment, 202010 acquisition of MD Biosciences Inc by MLM Medical Labs |
2020-10-26 |
| Cara Therapeutics–Vifor Pharma: investment, 202010 equity investment $50m in connection with US license agreement for Korsuva |
2020-10-20 |
| ChromoTek–Proteintech: investment, 202010 acquisition of ChromoTek by Proteintech Group |
2020-10-20 |
| Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BioMedPartners plus all existing investors |
2020-10-19 |
| Azitra–SEVERAL: investment, 202010 financing round Series B $17m led by Leaps by Bayer |
2020-10-15 |
| VectivBio–SEVERAL: investment, 202010 crossover financing $110m from existing + new investors |
2020-10-15 |
| RayzeBio–SEVERAL: investment, 202010 financing round Series A $45m co-led by venBio Partners + Versant Ventures |
2020-10-14 |
| Chord Therapeutics–Omega Funds: investment, 202010 financing Series A $16m from sole investor Omega Funds |
2020-10-13 |
| Iksuda Therapeutics–Univ Göttingen: antibody-drug conjugates, 202010– license excl ww to new class of prodrug payloads for ADCs using PermaLink |
2020-10-13 |
| Rappta Therapeutics–SEVERAL: investment, 202010 financing round Series A €9m co-led by NVF + Novo Seeds |
2020-10-13 |
| Priothera–SEVERAL: investment, 202010 financing round Series A €30m led by Fountain Healthcare Partners |
2020-10-12 |
| Sensei Biotherapeutics–SEVERAL: investment, 202010 financing round Series A $28.5m co-led by Cambrian Biopharma + H&S Ventures |
2020-10-07 |
| Novartis–Merck (DE): Nanobodies, 202010– license €50m upfront + €400m milestones to M6495 anti-ADAMTS5 Nanobody for osteoarthritis |
2020-10-06 |
| BIA Separations–Sartorius: investment, 202010– acquisition €240m in cash + €120m in SSB shares BIA to be merged into SSB ANNOUNCED |
2020-10-02 |
| Sophia Genetics–SEVERAL: investment, 202010 financing round Series F $110m led by aMoon + Hitachi Ventures |
2020-10-01 |
| Wise (IT)–SEVERAL: investment, 202010 financing round Series C €15m led by CDP Venture Capital SGR |
2020-10-01 |
| Integrated Proteomics Applications–Bruker: investment, 202009 acquisition €na of assets by Bruker |
2020-09-30 |
| Dewpoint Therapeutics–SEVERAL: investment, 202009 financing round Series B $77m led by ARCH Venture Partners |
2020-09-29 |
| Prolytic–Kymos: investment, 202009 strategic merger of Polytic GmbH + Kymos SL |
2020-09-28 |
| XtalPi–SEVERAL: investment, 202009 financing round Series C $318.8m co-led by SoftBank Vision Fund 2 + PICC Capital + Morningside |
2020-09-28 |
| Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Ventures |
2020-09-25 |
| Mosa Meat–SEVERAL: investment, 202009 financing round Series B 1st closing $55m led by Blue Horizon Ventures |
2020-09-25 |
| Monte Rosa Therapeutics–SEVERAL: investment, 202009 financing round Series B $96m led by AIsling Capital |
2020-09-24 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
